Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: This study explored the relationship between integrase strand transfer inhibitor (INSTI)-based anti-retroviral agents and weight gain over time, and the risk factors for weight gain in Korean people living with human immunodeficiency virus (PLWH). Materials and methods: The study was conducted retrospectively in PLWHs 18 years of age or older who took one of three INSTI-based single-tablet regimens (STRs) (tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat [TDF/F/EVG/c], tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat [TAF/F/EVG/c], and abacavir/lamivudine/dolutegravir [ABC/3TC/DTG]) for more than 2 years at three university-affiliated hospitals in South Korea from May 2014 to December 2020. Analysis was performed in the treatment-naïve and treatment-experienced groups, respectively. Results: Individual INSTI-based STRs were associated with weight gain at the 24-month follow up in both treatment-naïve (n = 179) and treatment-experienced (n = 290) groups. Body mass index (BMI) categories changed over time for TAF/F/EVG/c and ABC/3TC/DTG, with significant increases in the rates of overweight and obesity in treatment-naïve patients, whereas there was no change for TDF/F/EVG/c. TAF/F/EVG/c significantly increased total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) compared to other regimens over 24 months. In the treatment-naïve group, a baseline CD4+ T cell count <100 cells/mm3, human immunodeficiency virus (HIV) viral load (VL) ≥100,000 copies/mL, no physical exercise, and TAF/F/EVG/c (vs. TDF/F/EVF/c) were risk factors for ≥10% weight gain. In the treatment-experienced group, age <45 years, BMI <25 kg/m², and no physical exercise were risk factors for ≥5% weight gain. Conclusion: INSTI-based STR continued to increase body weight at the 24-month follow up in treated and untreated Korean PLWH. Exercise, together with demographic-, HIV-, and anti-retroviral therapy-related factors, influenced weight gain. Therefore, when prescribing an INSTI-based STR, weight gain and metabolic changes should be closely monitored in PLWH with these risk factors.
Abstract
Background: This study explored the relationship between integrase strand transfer inhibitor (INSTI)-based anti-retroviral agents and weight gain over time, and the risk factors for weight gain in Korean people living with human immunodeficiency virus (PLWH). Materials and methods: The study was conducted retrospectively in PLWHs 18 years of age or older who took one of three INSTI-based single-tablet regimens (STRs) (tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat [TDF/F/EVG/c], tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat [TAF/F/EVG/c], and abacavir/lamivudine/dolutegravir [ABC/3TC/DTG]) for more than 2 years at three university-affiliated hospitals in South Korea from May 2014 to December 2020. Analysis was performed in the treatment-naïve and treatment-experienced groups, respectively. Results: Individual INSTI-based STRs were associated with weight gain at the 24-month follow up in both treatment-naïve (n = 179) and treatment-experienced (n = 290) groups. Body mass index (BMI) categories changed over time for TAF/F/EVG/c and ABC/3TC/DTG, with significant increases in the rates of overweight and obesity in treatment-naïve patients, whereas there was no change for TDF/F/EVG/c. TAF/F/EVG/c significantly increased total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) compared to other regimens over 24 months. In the treatment-naïve group, a baseline CD4+ T cell count <100 cells/mm3, human immunodeficiency virus (HIV) viral load (VL) ≥100,000 copies/mL, no physical exercise, and TAF/F/EVG/c (vs. TDF/F/EVF/c) were risk factors for ≥10% weight gain. In the treatment-experienced group, age <45 years, BMI <25 kg/m², and no physical exercise were risk factors for ≥5% weight gain. Conclusion: INSTI-based STR continued to increase body weight at the 24-month follow up in treated and untreated Korean PLWH. Exercise, together with demographic-, HIV-, and anti-retroviral therapy-related factors, influenced weight gain. Therefore, when prescribing an INSTI-based STR, weight gain and metabolic changes should be closely monitored in PLWH with these risk factors.
참고문헌 (32)
- Wandeler G, "Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe : comparisons with general population", Curr Opin HIV AIDS, 11, pp.492~500 (2016)
- Antiretroviral Therapy Cohort Collaboration, "Life expectancy of individuals on combination antiretroviral therapy in high-income countries : a collaborative analysis of 14 cohort studies", Lancet, 372, pp.293~299 (2008)
- "Guidelines for the use of antiretroviral agents in adults and adolescents with HIV"[URL]
- Ryom L, "Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021", HIV Med (2022)
- Kelly SG, "Initial antiretroviral therapy in an integrase inhibitor era : Can we do better?", Infect Dis Clin North Am, 33, pp.681~692 (2019)
- Messiaen P, "Clinical use of HIV integrase inhibitors : a systematic review and meta-analysis", PLoS One, 8, pp.e52562~ (2013)
- Cotte L, "Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy-Results from a large french multicenter cohort study", PLoS One, 12, pp.e0170661~ (2017)
- Sax PE, "Weight gain following initiation of antiretroviral therapy : Risk factors in randomized comparative clinical trials", Clin Infect Dis, 71, pp.1379~1389 (2020)
- Bourgi K, "Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy", Clin Infect Dis, 70, pp.1267~1274 (2020)
- Lakey W, "Short communication : from wasting to obesity : initial antiretroviral therapy and weight gain in HIV-infected persons", AIDS Res Hum Retroviruses, 29, pp.435~440 (2013)
- Achhra AC, "Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes : the D : A : D study", HIV Med, 17, pp.255~268 (2016)
- Eckard AR, "Weight gain and integrase inhibitors", Curr Opin Infect Dis, 33, pp.10~19 (2020)
- Norwood J, "Brief report : weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens", J Acquir Immune Defic Syndr, 76, pp.527~531 (2017)
- Bourgi K, "Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada", J Int AIDS Soc, 23, pp.e25484~ (2020)
- Kuo PH, "Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir", cobicistat, tenofovir alafenamide, pp.Int J Infect Dis, 2020[DOI]
- Ando N, "Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus", Int J Infect Dis, 110, pp.21~28 (2021)
- Ibeneme SC, "Impact of physical exercises on immune function, bone mineral density, and quality of life in people living with HIV", AIDS : a systematic review with meta-analysis, 2019, pp.19, 340~
- U.S. Preventive Services Task Force, "Screening for lipid disorders in children and adolescents : Recommendation statement", Am Fam Physician, 94 (2016)
- Obesity: preventing and managing the global epidemic. Report of a WHO consultation, "World Health Organization (WHO)", i~253, pp.World Health Organ Tech Rep Ser 894 (2000)
- Huhn GD, "Atherosclerotic cardiovascular disease risk profile of tenofovir alafenamide versus tenofovir disoproxil fumarate", Open Forum Infect Dis, 7, pp.ofz472~ (2019)
- Bekolo CE, "The lipid profile of HIV-infected patients receiving antiretroviral therapy in a rural Cameroonian population", BMC Public Health, 14, pp.236~ (2014)
- Grunfeld C, "Dyslipidemia and its treatment in HIV infection", Top HIV Med, 18, pp.112~118 (2010)
- Friis-Møller N, "Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study", AIDS, 17, pp.1179~1193 (2003)
- The RESPOND Study Group, "Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents", AIDS, 35, pp.869~882 (2021)
- Maggi P, "Cardiovascular risk and dyslipidemia among persons living with HIV : a review", BMC Infect Dis, 17, pp.551~ (2017)
- Kaplan RC, "Ten-year predicted coronary heart disease risk in HIV-infected men and women", Clin Infect Dis, 45, pp.1074~1081 (2007)
- Friis-Møller N, "Predicting the risk of cardiovascular disease in HIV-infected patients : the data collection on adverse effects of anti-HIV drugs study", Eur J Cardiovasc Prev Rehabil, 17, pp.491~501 (2010)
- Ryom L, "Cardiovascular disease and use of contemporary protease inhibitors : the D : A : D international prospective multicohort study", Lancet HIV, 5, pp.e291~300 (2018)
- Sinxadi PZ, "Plasma efavirenz concentrations are associated with lipid and glucose concentrations", Medicine(Baltimore), 95, pp.e2385~ (2016)
- O’Halloran JA, "Brief report : Integrase strand transfer inhibitors are associated with lower risk of incident cardiovascular disease in people living with HIV", J Acquir Immune Defic Syndr, 84, pp.396~399 (2020)
- Sarkar S, "CROI 2021 : Metabolic and other complications of HIV infection or COVID-19", Top Antivir Med, 29, pp.328~333 (2021)
- Jaggers JR, "Health benefits of exercise for people living with HIV : A review of the literature", Am J Lifestyle Med, 10, pp.184~192 (2014)